TENSIVE SRL

Their core work

Tensive is a Milano-based medical device SME developing resorbable breast implants designed to help cancer survivors reconstruct their natural breast after mastectomy. Their core technology induces the body's own tissue regeneration rather than relying on permanent synthetic implants, with the goal of restoring natural aesthetics without long-term foreign materials remaining in the body. The company moved from concept validation to full product development under the EU SME Instrument, progressing from a Phase 1 feasibility study to a Phase 2 innovation project worth nearly €1.9 million. Their work sits at the intersection of biomaterials science, oncology aftercare, and regenerative medicine.

What they specialise in

How they've shifted over time

Tensive's entire H2020 participation is a single, linear development arc: the REGENERA technology moved from a Phase 1 feasibility concept in 2016–2017 to a full Phase 2 development program from 2018 to 2021 — a 37-fold increase in funding. There is no pivot or sector shift; the organization deepened its focus on one specific technology rather than diversifying. This reflects a startup-style product development trajectory rather than a research portfolio strategy.

Tensive is a single-product company in late-stage development of a resorbable breast implant; future collaboration would most likely center on clinical validation, regulatory approval (CE/MDR), or commercialization partnerships rather than new research.

How they like to work

Tensive has acted exclusively as project coordinator in both H2020 projects, which under the SME Instrument is the norm — these grants are designed for individual SMEs driving their own innovation agenda. No consortium partners appear in the data, consistent with the SME Instrument's solo-applicant model. Working with them as a partner would likely mean joining them in a future consortium where they bring the core implant technology and seek clinical, regulatory, or manufacturing expertise from others.

No consortium partner data is available, consistent with the SME Instrument format which does not require multi-partner consortia. Tensive's EU-level network appears limited to the funding relationship with the European Commission rather than a broad collaborative ecosystem.

What sets them apart

Tensive occupies a narrow but high-value niche: resorbable implants specifically designed for breast reconstruction in cancer survivors, where the device disappears as the body rebuilds its own tissue. This addresses a well-documented unmet clinical need and differentiates from conventional silicone implants or tissue flap procedures. Their successful progression through both SME Instrument phases signals that the technology passed EU-level commercial feasibility scrutiny, giving potential partners a degree of validated credibility.

Highlights from their portfolio

• REGENERA
  The Phase 2 grant of €1,889,170 represents one of the larger SME Instrument Phase 2 awards and funds full development of a genuinely differentiated medical device targeting post-mastectomy reconstruction — a high-impact clinical application.
• REGENERA
  The Phase 1 award (2016) demonstrates that Tensive successfully cleared the EU's commercial feasibility gate before scaling investment, lending credibility to the underlying technology concept.